Novavax, Inc. (NVAX): Price and Financial Metrics
NVAX Price/Volume Stats
| Current price | $7.19 | 52-week high | $25.66 |
| Prev. close | $7.11 | 52-week low | $5.61 |
| Day low | $7.03 | Volume | 4,110,600 |
| Day high | $7.38 | Avg. volume | 7,245,537 |
| 50-day MA | $7.95 | Dividend yield | N/A |
| 200-day MA | $8.63 | Market Cap | 678.76M |
NVAX Stock Price Chart Interactive Chart >
NVAX POWR Grades
- NVAX scores best on the Value dimension, with a Value rank ahead of 91.89% of US stocks.
- The strongest trend for NVAX is in Growth, which has been heading up over the past 177 days.
- NVAX ranks lowest in Stability; there it ranks in the 0th percentile.
NVAX Stock Summary
- NOVAVAX INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 4.42% of US listed stocks.
- NVAX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 4.45% of US stocks.
- With a year-over-year growth in debt of -55.63%, NOVAVAX INC's debt growth rate surpasses just 4.76% of about US stocks.
- Stocks that are quantitatively similar to NVAX, based on their financial statements, market capitalization, and price volatility, are PLX, EXEL, GSIT, MRKR, and BCDA.
- Visit NVAX's SEC page to see the company's official filings. To visit the company's web site, go to www.novavax.com.
NVAX Valuation Summary
- NVAX's price/sales ratio is 0.4; this is 90% lower than that of the median Healthcare stock.
- NVAX's price/earnings ratio has moved up 8.7 over the prior 243 months.
Below are key valuation metrics over time for NVAX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NVAX | 2023-09-22 | 0.4 | -0.9 | -1.1 | -0.6 |
| NVAX | 2023-09-21 | 0.4 | -0.9 | -1.1 | -0.6 |
| NVAX | 2023-09-20 | 0.4 | -0.9 | -1.1 | -0.6 |
| NVAX | 2023-09-19 | 0.5 | -1.0 | -1.2 | -0.7 |
| NVAX | 2023-09-18 | 0.4 | -0.9 | -1.2 | -0.7 |
| NVAX | 2023-09-15 | 0.5 | -1.0 | -1.2 | -0.7 |
NVAX Growth Metrics
- The 3 year cash and equivalents growth rate now stands at 1390.08%.
- The 5 year revenue growth rate now stands at 7.39%.
- Its 4 year net income to common stockholders growth rate is now at 53.22%.
The table below shows NVAX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 1,981.872 | -415.937 | -657.939 |
| 2022-09-30 | 1,846.673 | -640.529 | -1,321.974 |
| 2022-06-30 | 1,290.94 | -743.964 | -1,475.792 |
| 2022-03-31 | 1,403.032 | -428.649 | -1,317.624 |
| 2021-12-31 | 1,146.29 | 322.946 | -1,743.751 |
| 2021-09-30 | 1,203.749 | 536.786 | -1,075.031 |
NVAX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NVAX has a Quality Grade of C, ranking ahead of 58.82% of graded US stocks.
- NVAX's asset turnover comes in at 0.6 -- ranking 60th of 680 Pharmaceutical Products stocks.
- GTHX, SRRA, and OPK are the stocks whose asset turnover ratios are most correlated with NVAX.
The table below shows NVAX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.600 | 1 | -14.595 |
| 2021-03-31 | 0.606 | 1 | -1.737 |
| 2020-12-31 | 0.502 | 1 | -0.781 |
| 2020-09-30 | 0.345 | 1 | -0.602 |
| 2020-06-30 | 0.126 | 1 | -0.222 |
| 2020-03-31 | 0.084 | 1 | -0.295 |
NVAX Price Target
For more insight on analysts targets of NVAX, see our NVAX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $264.20 | Average Broker Recommendation | 1.58 (Moderate Buy) |
Novavax, Inc. (NVAX) Company Bio
Novavax, Inc. focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company was founded in 1987 and is based in Gaithersburg, Maryland.
Latest NVAX News From Around the Web
Below are the latest news stories about NOVAVAX INC that investors may wish to consider to help them evaluate NVAX as an investment opportunity.
New COVID vaccine rollout running into insurance, supply roadblocksThe rollout of new COVID-19 vaccines is being obstructed by insurance and supply roadblocks, as customers experience issues with getting insurers to agree on vaccine coverage. The Department of Health and Human Services wrote a letter to insurers stating, "Your obligation as a plan or issuer to ensure that your members have coverage for COVID-19 vaccines without cost sharing is not conditional upon parties' compliance." Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. |
Is Novavax Stock A Sell As The FDA Holds Off On Approving Its Covid Vaccine?Novavax stock is under pressure after the FDA didn't approve its Covid shot with Pfizer's and Moderna's. Is NVAX stock a buy or a sell today? |
Does This Message From Moderna Mean Bad News for Novavax?Moderna (NASDAQ: MRNA) recently gave an update on its pipeline and future goals, and the biotech had a lot to say. This doesn't mean Moderna is forgetting about the coronavirus vaccine though. In fact, this market giant announced something that could impact smaller rival Novavax (NASDAQ: NVAX). |
Novavax and Invitae implement cost-cutting measures amid financial challengesIn the volatile world of stock trading, healthcare companies Novavax (NASDAQ:NVAX) and Invitae (NYSE:NVTA) have been making headlines as they navigate significant financial challenges. Both firms are taking measures to reduce costs, aiming to improve their financial standing and appeal to a broader range of investors. |
Moderna (MRNA) Receives CHMP Nod for Updated COVID VaccineClinical data from studies on Moderna's (MRNA) updated COVID vaccine shows improved antibody responses against multiple circulating variants, including BA.2.86, EG.5 and FL.1.5.1 variants. |
NVAX Price Returns
| 1-mo | -13.37% |
| 3-mo | -3.23% |
| 6-mo | 3.75% |
| 1-year | -63.34% |
| 3-year | -93.53% |
| 5-year | -80.88% |
| YTD | -30.06% |
| 2022 | -92.81% |
| 2021 | 28.30% |
| 2020 | 2,701.76% |
| 2019 | -89.18% |
| 2018 | 48.39% |
Continue Researching NVAX
Want to see what other sources are saying about Novavax Inc's financials and stock price? Try the links below:Novavax Inc (NVAX) Stock Price | Nasdaq
Novavax Inc (NVAX) Stock Quote, History and News - Yahoo Finance
Novavax Inc (NVAX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...